Diana E. Sepúlveda

1.9k total citations · 1 hit paper
22 papers, 1.4k citations indexed

About

Diana E. Sepúlveda is a scholar working on Pharmacology, Physiology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Diana E. Sepúlveda has authored 22 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pharmacology, 13 papers in Physiology and 5 papers in Cellular and Molecular Neuroscience. Recurrent topics in Diana E. Sepúlveda's work include Cannabis and Cannabinoid Research (12 papers), Pain Mechanisms and Treatments (10 papers) and Neuroscience and Neuropharmacology Research (4 papers). Diana E. Sepúlveda is often cited by papers focused on Cannabis and Cannabinoid Research (12 papers), Pain Mechanisms and Treatments (10 papers) and Neuroscience and Neuropharmacology Research (4 papers). Diana E. Sepúlveda collaborates with scholars based in United States, Argentina and Netherlands. Diana E. Sepúlveda's co-authors include Marjolein Visser, Richard N. Pierson, T. B. Harris, Steven B. Heymsfield, Dympna Gallagher, Wesley M. Raup‐Konsavage, Kent E. Vrana, Nicholas Graziane, Daniel P. Morris and Daniel J. Morgan and has published in prestigious journals such as American Journal of Epidemiology, The FASEB Journal and The American Journal of Sports Medicine.

In The Last Decade

Diana E. Sepúlveda

21 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

How Useful Is Body Mass Index for Comparison of Body Fatness across Age, Sex, and Ethnic Groups?

1996 1.2k citations Dympna Gallagher, Marjolein Visser et al. American Journal of Epidemiology profile →

Peers

Countries citing papers authored by Diana E. Sepúlveda

Since Specialization

Citations

This map shows the geographic impact of Diana E. Sepúlveda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diana E. Sepúlveda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diana E. Sepúlveda more than expected).

Fields of papers citing papers by Diana E. Sepúlveda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diana E. Sepúlveda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diana E. Sepúlveda. The network helps show where Diana E. Sepúlveda may publish in the future.

Co-authorship network of co-authors of Diana E. Sepúlveda

This figure shows the co-authorship network connecting the top 25 collaborators of Diana E. Sepúlveda. A scholar is included among the top collaborators of Diana E. Sepúlveda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diana E. Sepúlveda. Diana E. Sepúlveda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Potential of Cannabichromene (CBC) as a Therapeutic Agent 2024 ·Journal of Pharmacology and Experimental Therapeutics ·Diana E. Sepúlveda, Kent E. Vrana, Joshua J. Kellogg, Jordan E. Bisanz, Dhimant Desai, Nicholas Graziane, Wesley M. Raup‐Konsavage	13
2	High Cannabigerol Hemp Extract Moderates Colitis and Modulates the Microbiome in an Inflammatory Bowel Disease Model 2024 ·Journal of Pharmacology and Experimental Therapeutics ·Benjamin D. Anderson, Diana E. Sepúlveda, Rahul Nachnani, (unknown), Matthew Coates, (unknown), Jordan E. Bisanz, Joshua J. Kellogg, Wesley M. Raup‐Konsavage	5
3	Cannabinoid Tolerance in S426A/S430A x β-Arrestin 2 Knockout Double-Mutant Mice 2023 ·Journal of Pharmacology and Experimental Therapeutics ·(unknown), Diana E. Sepúlveda, (unknown), Josée Guindon, (unknown), Daniel J. Morgan	4
4	Chronic Cannabigerol as an Effective Therapeutic for Cisplatin-Induced Neuropathic Pain 2023 ·Pharmaceuticals ·Rahul Nachnani, Diana E. Sepúlveda, (unknown), Shouhao Zhou, Nicholas Graziane, Wesley M. Raup‐Konsavage, Kent E. Vrana	13
5	Antinociceptive Effects of Cannabichromene (CBC) in Mice: Insights from von Frey, Tail-Flick, Formalin, and Acetone Tests 2023 ·Biomedicines ·Wesley M. Raup‐Konsavage, Diana E. Sepúlveda, Jian Wang, Nikolay V. Dokholyan, Kent E. Vrana, Nicholas Graziane	12
6	Cannabidiol and Cannabigerol, Nonpsychotropic Cannabinoids, as Analgesics that Effectively Manage Bone Fracture Pain and Promote Healing in Mice 2023 ·Journal of Bone and Mineral Research ·Deepak Kumar Khajuria, Vengadeshprabhu Karuppagounder, (unknown), Diana E. Sepúlveda, Gregory S. Lewis, Christopher C. Norbury, Wesley M. Raup‐Konsavage, Kent E. Vrana, Fadia Kamal, Reyad A. Elbarbary	13
7	Therapeutic Effects of Non-Euphorigenic Cannabis Extracts in Osteoarthritis 2022 ·Cannabis and Cannabinoid Research ·Vengadeshprabhu Karuppagounder, (unknown), (unknown), Amy Thompson, (unknown), (unknown), (unknown), Diana E. Sepúlveda, Wesley M. Raup‐Konsavage, Nicholas Graziane, Kent E. Vrana, Reyad A. Elbarbary, Fadia Kamal	7
8	Decursinol-mediated antinociception and anti-allodynia in acute and neuropathic pain models in male mice: Tolerance and receptor profiling 2022 ·Frontiers in Pharmacology ·(unknown), (unknown), Deepkamal Karelia, Diana E. Sepúlveda, Daniel J. Morgan, Junxuan Lü, (unknown)	2
9	Combinations of Cannabidiol and Δ9-Tetrahydrocannabinol in Reducing Chemotherapeutic Induced Neuropathic Pain 2022 ·Biomedicines ·Diana E. Sepúlveda, Kent E. Vrana, Nicholas Graziane, Wesley M. Raup‐Konsavage	13
10	Cannabigerol (CBG) attenuates mechanical hypersensitivity elicited by chemotherapy‐induced peripheral neuropathy 2022 ·European Journal of Pain ·Diana E. Sepúlveda, Daniel P. Morris, Wesley M. Raup‐Konsavage, Dongxiao Sun, Kent E. Vrana, Nicholas Graziane	26
11	Evaluating the Antinociceptive Efficacy of Cannabidiol Alone or in Combination with Morphine Using the Formalin Test in Male and Female Mice 2021 ·Cannabis and Cannabinoid Research ·Diana E. Sepúlveda, Daniel P. Morris, Wesley M. Raup‐Konsavage, Dongxiao Sun, Kent E. Vrana, Nicholas Graziane	18
12	Sex-specific mechanisms of tolerance for the cannabinoid agonists CP55,940 and delta-9-tetrahydrocannabinol (Δ9-THC) 2021 ·Psychopharmacology ·(unknown), Diana E. Sepúlveda, (unknown), (unknown), (unknown), Daniel J. Morgan	7
13	Sex Differences in Tolerance to Delta-9-Tetrahydrocannabinol in Mice With Cisplatin-Evoked Chronic Neuropathic Pain 2021 ·Frontiers in Molecular Biosciences ·(unknown), (unknown), Diana E. Sepúlveda, David Hale, (unknown), Daniel J. Morgan	17
14	Biomechanical Effects of Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD), the Major Constituents of Cannabis, in a Sprague Dawley Rat Achilles Tendon Surgical Repair Model: A Pilot Study 2021 ·The American Journal of Sports Medicine ·(unknown), (unknown), Diana E. Sepúlveda, Michael Aynardi, Matthew R. Garner, Gregory S. Lewis, Daniel J. Morgan, Aman Dhawan	4
15	c-Jun N terminal kinase signaling pathways mediate cannabinoid tolerance in an agonist-specific manner 2019 ·Neuropharmacology ·(unknown), (unknown), Brian J. Davis, (unknown), Diana E. Sepúlveda, Henry Blanton, (unknown), (unknown), (unknown), David Marcus, Ken Mackie, Josée Guindon, Daniel J. Morgan	21
16	Carbonic anhydrase inhibitors reduce cardiac dysfunction after sustained coronary artery ligation in rats 2016 ·Cardiovascular Pathology ·(unknown), (unknown), Romina G. Díaz, Diana E. Sepúlveda, Erik R. Swenson, Néstor G. Pérez, Bernardo V. Álvarez	12
17	Mesenchymal stromal cells overexpressing vascular endothelial growth factor in ovine myocardial infarction 2015 ·Gene Therapy ·(unknown), (unknown), (unknown), (unknown), Magdalena Cerdá, (unknown), Diana E. Sepúlveda, R Laguens, Alberto Crottogini	22
18	Activated macrophages as a feeder layer for growth of resident cardiac progenitor cells 2014 ·Cytotechnology ·Diana E. Sepúlveda, Patricia Cabeza Meckert, (unknown), (unknown), Néstor G. Pérez, (unknown), Romina G. Díaz, Alberto Crottogini, Rubén P. Laguens	3
19	Efficient plasmid-mediated gene transfection of ovine bone marrow mesenchymal stromal cells 2013 ·Cytotherapy ·(unknown), (unknown), (unknown), Diana E. Sepúlveda, Juan M. Pérez Sáez, Rafael J. Argüello, Alberto Crottogini	14
20	How Useful Is Body Mass Index for Comparison of Body Fatness across Age, Sex, and Ethnic Groups? breakdown → 1996 ·American Journal of Epidemiology ·Dympna Gallagher, Marjolein Visser, Diana E. Sepúlveda, Richard N. Pierson, T. B. Harris, Steven B. Heymsfield	1160

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact